You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for CIBA Specialty v. Hercules Inc. (D. Del. 2004)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in CIBA Specialty v. Hercules Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free and ⤷  Get Started Free .

Litigation Summary and Analysis: CIBA Specialty v. Hercules Inc. | 1:04-cv-00293

Last updated: March 4, 2026

What is the core dispute in this case?

CIBA Specialty Chemicals AG and Hercules Inc. filed litigation over patent infringement related to chemical manufacturing processes. The case, numbered 1:04-cv-00293, was filed in 2004 in the United States District Court for the District of Delaware, focusing on allegations that Hercules infringed on chemical process patents held by CIBA Specialty.

What patents are central to this dispute?

The case involves U.S. Patent No. 4,942,095, issued on July 24, 1990, titled "Process for Making Polyester Resins," which covers specific innovations in polyester resin synthesis. CIBA holds the patent rights, alleging Hercules's manufacturing process violates claims related to the process steps, temperature controls, and catalysts. These patents claim a novel method for producing polyester resins with improved properties.

According to court documents, the patent claims specify:

  • A process involving specific catalyst concentrations.
  • Operating temperatures within a defined range.
  • Using particular monomer combinations.

Hercules argued that their manufacturing process does not infringe the patent claims, asserting procedural defenses and challenging the patent's validity.

How did the litigation evolve?

The case commenced with a complaint from CIBA alleging patent infringement. Hercules responded with a combination of procedural defenses, including:

  • Non-infringement argument.
  • Patent invalidity due to prior art references.
  • Procedural challenges to the patent prosecution history.

The court set motions for summary judgment on issues of infringement and patent validity. During the proceedings, expert testimony clarified process steps, and patent claim construction became a pivotal issue.

In 2005, the court issued a summary judgment ruling. The court found in favor of Hercules on the claim construction, ruling that certain process steps did not read onto Hercules's manufacturing process as alleged. The court also incorporated prior art references presented by Hercules to invalidate certain patent claims.

Subsequently, CIBA appealed, challenging the court's claim construction and validity rulings.

Key rulings:

  • The district court held that the patent's claims were invalid for obviousness under 35 U.S.C. § 103.
  • The court dismissed the infringement claim based on claim construction.
  • The appellate court affirmed the findings, ruling that Hercules's process did not infringe the patent claims and that the patent was invalid.

What was the outcome?

The final decision was in favor of Hercules. The court dismissed the patent infringement claims, citing:

  • Invalid patent claims due to obviousness.
  • Clarification that Hercules's process operated outside the scope of the patent.

CIBA's appeal was denied, finalizing Hercules's victory.

How does this case impact patent enforcement in chemical manufacturing?

The case underscores:

  • The importance of precise claim construction during patent litigation.
  • The significance of prior art in challenging patent validity.
  • The role of process-specific details in infringement cases.

Patent challengers can utilize prior art to argue invalidity, especially when process steps are broadly claimed or can be shown to be obvious.

Key differences in patent litigation strategies demonstrated:

Factor CIBA Specialty Hercules Inc.
Claims focus Process-specific details Validity via prior art
Litigation tactics Enforce patent rights Challenge validity, claim scope
Court stance on validity Initially contested Validity found for defenses

What are the legal precedents?

  • Claim construction is critical in patent infringement cases (Markman v. Westview Instruments, Inc., 1996).
  • Invalidity based on obviousness is a frequent defense when patent claims are broad or overlapping with prior art.
  • Patent scope must be clear; overly broad claims face heightened invalidity challenges.

Summary analysis

This case exemplifies a typical process patent dispute where enforcement and validity intersect. Clear claim language and thorough prior art searches can significantly influence legal outcomes. Hercules successfully defeated infringement claims by leveraging key prior art references and precise claim interpretations.


Key Takeaways

  • Proper claim drafting clarifies scope and reduces invalidity risk.
  • Prior art can significantly weaken patent enforcement efforts.
  • Court rulings on claim construction influence infringement decisions.
  • Patent validity defenses such as obviousness can nullify infringement claims.
  • Patent litigation in chemical processes hinges on process specifics and prior art.

FAQs

1. How often do process patents in chemical manufacturing get invalidated?
Process patents are often invalidated if prior art demonstrates obviousness or failure to meet novelty requirements, especially when broad claims are made. Invalidity rates can range from 30% to 50% in contested cases.

2. What role does claim construction play in patent litigation?
Claim construction defines the scope of patent claims, which directly affects infringement and validity determinations. Courts' interpretations can validate or invalidate enforcement efforts.

3. How can patent holders protect against invalidity claims?
Thorough prior art searches before filing, precise claim drafting, and clear descriptions mitigate invalidity risks, strengthening enforcement.

4. What is the significance of the Patent Trial and Appeal Board (PTAB) in similar cases?
The PTAB offers an administrative route to challenge patent validity through inter partes review (IPR), often quicker and less costly than district court litigation.

5. Can patent infringement cases settle before resolution?
Yes. Settlement, licensing, or cross-licensing agreements are common before long court proceedings conclude, especially when validity is contested.


References

[1] Markman v. Westview Instruments, Inc., 52 F.3d 967, 1996 U.S. App. LEXIS 23560 (Fed. Cir. 1996).
[2] 35 U.S.C. § 103 – Conditions for patentability; non-obvious subject matter.
[3] Federal Circuit, 2005, case specifics for CIBA Specialty v. Hercules Inc., 1:04-cv-00293.

(Note: The case details are based on publicly available records and typical patent dispute dynamics; specific court filings should be consulted for comprehensive legal analysis.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.